Robert Lutz
Seminars
Tuesday 9th March 2027
CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies
9:30 am
- Understanding the 2027 ADC landscape and how the bar has been raised to develop and deliver ADCs with meaningful patient impact
- Outlining the future opportunities and applications on the horizon for ADCs to achieve target differentiation and clinical safety
- Highlighting methods to best pursue ADC clinical differentiation across patient selection technologies, combination strategies, and well-executed clinical design
- With clinical trials advancing in the Far East and Australia, what opportunities does this open for the ADC industry to progress faster?
Tuesday 9th March 2027
Panel Discussion: Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation
5:00 pm
- Debating the optimal chemical and biological properties of next-generation payload and linker combinations
- Exploring the novelty of dual-payload ADCs and their potential to overcome resistance mechanisms associated with traditional ADCs
- Assessing the potential of novel ‘XDC’ candidates to expand therapeutic applications and unlock untapped opportunities within an increasingly crowded ADC landscape
Wednesday 10th March 2027
Novel ADC Designs Drive Improved Clinical Outcomes
- Update on clinical progress for next generation ADCs, IKS014 and IKS03
- Differentiation through ADC design to address competitive landscape
- ADC innovation paving the way for novel payloads
Thursday 11th March 2027
Leveraging Clinical Outcomes & Performance to Inform the Development of Novel ADC Design
1:00 pm
This workshop will focus on improving translatability of pre-clinical findings to first-in human studies that maximise learning while ensuring patient safety. It will be an opportunity to discuss back-translation strategies to inform next-generation ADC design.
Key Questions:
- Which ADC designs demonstrate the best clinical efficacy and outcomes by overcoming resistance challenges?
- How do we establish human dose projections from pre-clinical studies?
- What can we learn from clinical failures to improve current ADC designs?
